In a groundbreaking development for diagnostic medicine, a recent clinical study has validated the Sysmex PA-100 AST system’s effectiveness in detecting bacteriuria—bacteria in the urine—and performing antimicrobial susceptibility tests (AST) within just 45 minutes. Evaluated for the first time at Fundació Puigvert, this technology is poised to revolutionize the diagnosis and treatment of urinary tract infections (UTIs), optimizing antibiotic use and mitigating the spread of antimicrobial resistance.
The PA-100 AST employs nanofluidic technology and phase contrast microscopy to identify the presence of bacteria in the urine. It quickly scans for common UTI-causing bacteria such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus. Once bacteria are identified, the system tests their susceptibility to five key antibiotics: amoxicillin/clavulanic acid, ciprofloxacin, fosfomycin, nitrofurantoin, and trimethoprim. This is done by exposing the bacteria to these antibiotics and observing their growth response, which helps determine which antibiotics are effective.
Led by Dr. Carles Alonso-Tarrés and Dr. Jaume Borràs from Fundació Puigvert, with support from Sant Pau Hospital and Sysmex Astrego, the study compared Sysmex PA-100 AST results against routine microbiology methods in 278 women with suspected uncomplicated UTIs. The findings, published in the European Journal of Clinical Microbiology & Infectious Diseases, reveal that the Sysmex PA-100 AST delivers bacteriuria results in 15 minutes and AST results in 45 minutes, boasting 84% sensitivity and 99.4% specificity for common UTI-causing bacteria.
The Sysmex PA-100 AST addresses a significant challenge: the traditional method of culturing bacteria takes 2-4 days, often leading to empirical antibiotic use and contributing to resistance. With UTI being one of the most common infections globally, affecting up to 400 million people annually, this rapid diagnostic tool is crucial.
Recognized by the UK’s Challenge Works with the Longitude Prize and featured in The Lancet, Sysmex PA-100 AST represents a pivotal advance in combating antimicrobial resistance, offering precise, timely diagnostics that could enhance patient care and public health.
Article written by IMMedico
09/09/2024
Source:
IMMédico
https://www.immedicohospitalario.es/noticia/47554/prueban-la-eficacia-de-un-nuevo-sistema-que-permite-identificar-en-45.html